Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

17 Mar 2025

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

Dermatology — Incyte hopes to compete with biologics in hidradenitis suppurativa • Source: Shutterstock

Planning for top-seller Jakafi’s (ruxolitinib) US patent expiration in 2028, Incyte reported positive top-line data from a pair of Phase III trials of selective JAK1 inhibitor povorcitinib in hidradenitis suppurativa on 17 March, but while the studies met their primary endpoint, questions remained about where the drug would fit in a disease with entrenched biologic therapies.

Key Takeaways

Incyte met the primary endpoint in two Phase III trials of povorcitinib in hidradenitis suppurativa, one of five indications in which the JAK1 inhibitor is being studied.

Incyte has long positioned povorcitinib to address anticipated generic revenue erosion for Jakafi, advancing the daily oral drug to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

13 Jun 2025

• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

13 Jun 2025

• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

12 Jun 2025

• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.